	US 12,467,052 B2
	Striatin interacting protein inhibitor and use thereof in preparation of anti-tumor drug
Gongchu Li, Zhejiang (CN)
Assigned to HANGZHOU GONGCHU BIOTECHNOLOGY CO., LTD., Hangzhou (CN)
Appl. No. 17/286,486
Filed by HANGZHOU GONGCHU BIOTECHNOLOGY CO., LTD., Zhejiang (CN)
PCT Filed Oct. 12, 2019, PCT No. PCT/CN2019/110713 § 371(c)(1), (2) Date Apr. 18, 2021, PCT Pub. No. WO2020/078274, PCT Pub. Date Apr. 23, 2020.
Claims priority of application No. 201811215763.2 (CN), filed on Oct. 18, 2018.
Prior Publication US 2022/0275370 A1, Sep. 1, 2022
Int. Cl. C12N 15/113 (2010.01); A61K 35/768 (2015.01); A61P 35/00 (2006.01)

CPC C12N 15/1137 (2013.01) [A61K 35/768 (2013.01); A61P 35/00 (2018.01); C12N 2310/14 (2013.01); C12N 2310/531 (2013.01); C12N 2710/24132 (2013.01); C12N 2710/24143 (2013.01)]

5 Claims

1. A method for treating a tumor in a subject in need thereof, comprising:

administering a therapeutically effective amount of striatin interacting protein (STRIP) inhibitors to the subject;

wherein a striatin interacting protein is STRIP1; and

the STRIP inhibitors are short hairpin RNA whose sequences are shown as SEQ ID No. 1, SEQ ID No. 2 or SEQ ID No. 3.